Drugs & Therapy Perspectives

, Volume 13, Issue 1, pp 1–4 | Cite as

Brimonidine: a useful new topical treatment for glaucoma and ocular hypertension

New Drugs and Disease Management
  • 11 Downloads

Keywords

Glaucoma Timolol Pilocarpine Latanoprost Ocular Hypertension 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Quigley HA. Open-angle glaucoma. N Engl J Med 1993 Apr; 328(15): 1097–106PubMedCrossRefGoogle Scholar
  2. 2.
    Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998 Mar; 12(3): 225–41PubMedCrossRefGoogle Scholar
  3. 3.
    Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104: 131–6PubMedGoogle Scholar
  4. 4.
    Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: S39–47PubMedCrossRefGoogle Scholar
  5. 5.
    Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: 27–37CrossRefGoogle Scholar
  6. 6.
    Gandolfi SA. The additive effect of brimonidine 0.2% BID compared with pilocarpine 2.0% TID in patients on beta-blocker monotherapy (abstract). Joint European Research Meeting in Ophthalmology and Vision (JERMOV); 1997 Oct 15–19: MontpelierGoogle Scholar
  7. 7.
    Allergan Limited. Alphagan®. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998–99. London: Datapharm Publications Ltd: 54–5Google Scholar
  8. 8.
    Allergan Inc. Brimonidine tartrate. PDR Generics 1998. Montvale (NJ): Medical Economics: 375Google Scholar
  9. 9.
    Abel Jr RS, Abel AD. Ocular diseases. In: Speight TM, Holford NHG, editors. Avery’s drug treatment. 4th ed. Auckland: Adis International Limited, 1997: 581–605Google Scholar
  10. 10.
    Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging 1992 May–Jun; 2: 208–21PubMedCrossRefGoogle Scholar
  11. 11.
    Patel SS, Spencer CM. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996 Nov; 9: 363–78PubMedCrossRefGoogle Scholar
  12. 12.
    Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994 Sep; 5: 156–70PubMedCrossRefGoogle Scholar
  13. 13.
    Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997 May; 10: 384–403PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations